{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:06:27Z","timestamp":1783908387001,"version":"3.55.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2020-0020_s_007_w2aab3b7b5b1b6b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      We assessed the prevalence, localization, type and outcome of occult cancer at risk-reducing salpingo-oophorectomy or salpingectomy (RRSO) in asymptomatic carriers of pathogenic or likely pathogenic\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      variants and high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      negative women.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0020_s_008_w2aab3b7b5b1b6b1aab1c16b2Aa\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis of all consecutive gynaecologic preventive surgeries from January 2009 to December 2015 was performed. Participants underwent genetic counselling and\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      testing before the procedure. Data on clinical parameters, adjuvant treatment and follow-up were collected and analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0020_s_009_w2aab3b7b5b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and fifty-five RRSO were performed in 110\n                      <jats:italic>BRCA1<\/jats:italic>\n                      , 35\n                      <jats:italic>BRCA2<\/jats:italic>\n                      carriers of pathogenic or likely pathogenic variants and 10 high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      negative women, at the mean age of 48.3 years. Nine occult cancers (9\/155, 5.8%) were identified; eight in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      positive women and one in high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      negative woman. We identified four non-invasive serous intraepithelial tubal carcinomas (3 in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers and 1 in a high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      negative woman) and five invasive tubo-ovarian high grade serous cancers (all detected in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      carriers). Only one out of nine patients (11.1%) with occult cancer had a slightly elevated CA-125 value preoperatively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0020_s_010_w2aab3b7b5b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A 5.8% prevalence of occult invasive and noninvasive tubo-ovarian serous cancer after RRSO was found in high risk asymptomatic and screen negative women. We conclude that RRSO should be performed in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      carriers and in high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      negative women. Age of preventive gynaecologic surgery should be carefully planned, taking into account the completion of childbearing age and type of mutation. The results favour the tubal hypothesis of tubal origin of high grade serous ovarian and peritoneal cancer. Cytology result of peritoneal cavity washing was important for the decision making process in determining treatment. Cytology examination should be performed in all cases of RRSO. CA-125 assay did not prove to be an effective screening tool for early cancer detection in our patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2020-0020","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T04:56:16Z","timestamp":1590641776000},"page":"180-186","source":"Crossref","is-referenced-by-count":6,"title":["The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients \u2013 Slovenian population based study"],"prefix":"10.2478","volume":"54","author":[{"given":"Andreja","family":"Gornjec","sequence":"first","affiliation":[{"name":"Department for Gynaecological Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastijan","family":"Merlo","sequence":"additional","affiliation":[{"name":"Department for Gynaecological Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdjan","family":"Novakovic","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Department, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Stegel","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Department, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gazic","sequence":"additional","affiliation":[{"name":"Pathology Department, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andraz","family":"Perhavec","sequence":"additional","affiliation":[{"name":"Department for Surgical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blatnik","sequence":"additional","affiliation":[{"name":"Cancer Genetics Clinic, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[{"name":"Cancer Genetics Clinic, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2026071213222502020_j_raon-2020-0020_ref_001_w2aab3b7b5b1b6b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144:1941-53. doi: 10.1002\/ijc.31937","DOI":"10.1002\/ijc.31937"},{"key":"2026071213222502020_j_raon-2020-0020_ref_002_w2aab3b7b5b1b6b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515\/raon-2017-0008","DOI":"10.1515\/raon-2017-0008"},{"key":"2026071213222502020_j_raon-2020-0020_ref_003_w2aab3b7b5b1b6b1ab2ab3Aa","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-16. doi: 10.1001\/ jama.2017.7112"},{"key":"2026071213222502020_j_raon-2020-0020_ref_004_w2aab3b7b5b1b6b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-22. doi: 10.1093\/jnci\/djt095","DOI":"10.1093\/jnci\/djt095"},{"key":"2026071213222502020_j_raon-2020-0020_ref_005_w2aab3b7b5b1b6b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30. doi: 10.1086\/375033","DOI":"10.1086\/375033"},{"key":"2026071213222502020_j_raon-2020-0020_ref_006_w2aab3b7b5b1b6b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, at al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2018; 150: 85-91. doi: 10.1016\/j.ygyno.2018.05.011","DOI":"10.1016\/j.ygyno.2018.05.011"},{"key":"2026071213222502020_j_raon-2020-0020_ref_007_w2aab3b7b5b1b6b1ab2ab7Aa","unstructured":"Guidelines for assessment of ovarian cancer patients [Slovenian]. Ljubljana: Institute of Oncology Ljubljana; 2016. [cites 2019 Nov 13]. Available from: https:\/\/www.onko-i.si\/dejavnosti\/zdravstvena-dejavnost\/priporocila-in-klinicne-poti\/priporocila"},{"key":"2026071213222502020_j_raon-2020-0020_ref_008_w2aab3b7b5b1b6b1ab2ab8Aa","unstructured":"Guidelines for diagnosis and treatment of breast cancer. [cites 2019 Nov 14]. Ljubljana: Institute of Oncology Ljubljana; 2018. Available from: https:\/\/ www.onko-i.si\/fileadmin\/onko\/datoteke\/Smernice\/Smernice_diagnostike_in_zdravljenja_raka_dojk_2018.pdf"},{"key":"2026071213222502020_j_raon-2020-0020_ref_009_w2aab3b7b5b1b6b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-93. doi: 10.1200\/JCO.2008.18.1107","DOI":"10.1200\/JCO.2008.18.1107"},{"key":"2026071213222502020_j_raon-2020-0020_ref_010_w2aab3b7b5b1b6b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1\/2 mutations. Gynecol Oncol 2018; 150: 79-84. doi: 10.1016\/j.ygyno.2018.04.564","DOI":"10.1016\/j.ygyno.2018.04.564"},{"key":"2026071213222502020_j_raon-2020-0020_ref_011_w2aab3b7b5b1b6b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-6. doi: 10.1006\/gyno.2002.6779","DOI":"10.1006\/gyno.2002.6779"},{"key":"2026071213222502020_j_raon-2020-0020_ref_012_w2aab3b7b5b1b6b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-90. doi: 10.1200\/JCO.2007.12.2622","DOI":"10.1200\/JCO.2007.12.2622"},{"key":"2026071213222502020_j_raon-2020-0020_ref_013_w2aab3b7b5b1b6b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes and 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 2009; 17: 1381-5. doi: 10.1038\/ejhg.2009.60","DOI":"10.1038\/ejhg.2009.60"},{"key":"2026071213222502020_j_raon-2020-0020_ref_014_w2aab3b7b5b1b6b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Reitsma W, De Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJE. Support of the \u201cfallopian tube hypothesis\u201d in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013; 49: 132-41. doi: 10.1016\/j.ejca.2012.07.021","DOI":"10.1016\/j.ejca.2012.07.021"},{"key":"2026071213222502020_j_raon-2020-0020_ref_015_w2aab3b7b5b1b6b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG An Int J Obstet Gynaecol 2011; 118: 814-24. doi: 10.1111\/j.1471-0528.2011.02920","DOI":"10.1111\/j.1471-0528.2011.02920.x"},{"key":"2026071213222502020_j_raon-2020-0020_ref_016_w2aab3b7b5b1b6b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013; 129: 364-71. doi.: org\/10.1016\/j.ygyno.2013.01.029","DOI":"10.1016\/j.ygyno.2013.01.029"},{"key":"2026071213222502020_j_raon-2020-0020_ref_017_w2aab3b7b5b1b6b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group trial GOG-0199. J Clin Oncol 2014; 32: 3275-83. doi: 10.1200\/JCO.2013.54.1987","DOI":"10.1200\/JCO.2013.54.1987"},{"key":"2026071213222502020_j_raon-2020-0020_ref_018_w2aab3b7b5b1b6b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Thompson C, McCormick C, Kamran W, O\u2019Riain C, Norris L, Gallagher D, et al. Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes. Ir J Med Sci 2018; 187: 789-94. doi: 10.1007\/s11845-017-1717-6","DOI":"10.1007\/s11845-017-1717-6"},{"key":"2026071213222502020_j_raon-2020-0020_ref_019_w2aab3b7b5b1b6b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, et al. Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series. Anticancer Res 2017; 37: 5241-48. doi: 10.21873\/anticanres.11948","DOI":"10.21873\/anticanres.11948"},{"key":"2026071213222502020_j_raon-2020-0020_ref_020_w2aab3b7b5b1b6b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up. Gynecol Oncol 2019; 153: 326-34. doi: 10.1016\/j. ygyno.2019.03.003","DOI":"10.1016\/j.ygyno.2019.03.003"},{"key":"2026071213222502020_j_raon-2020-0020_ref_021_w2aab3b7b5b1b6b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol 2016; 143: 231-35. doi: 10.1016\/j. ygyno.2016.08.336","DOI":"10.1016\/j.ygyno.2016.08.336"},{"key":"2026071213222502020_j_raon-2020-0020_ref_022_w2aab3b7b5b1b6b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D. A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy. Int J Surg Case Rep 2018; 52: 107-10. doi: 10.1016\/j.ijscr.2018.10.014","DOI":"10.1016\/j.ijscr.2018.10.014"},{"key":"2026071213222502020_j_raon-2020-0020_ref_023_w2aab3b7b5b1b6b1ab2ac23Aa","unstructured":"Clarke BA, Crum CP, Nucci, MR, Oliva MR. Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. Based on AJCC\/UICC TNM, 7th edition, and FIGO 2006 Annual Report. [cites 2019 Nov 15]. Available from: http:\/\/webapps.cap.org\/apps\/docs\/committees\/cancer\/cancer_protocols\/2013\/FallopianTube_13protocol_3101.pdf"},{"key":"2026071213222502020_j_raon-2020-0020_ref_024_w2aab3b7b5b1b6b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"Finch APM, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014; 32: 1547-53. doi: 10.1200\/ JCO.2013.53.2820","DOI":"10.1200\/JCO.2013.53.2820"},{"key":"2026071213222502020_j_raon-2020-0020_ref_025_w2aab3b7b5b1b6b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Henry T, Isaacs C, et al. Europe PMC funders group association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-75. doi: 10.1001\/jama.2010.1237","DOI":"10.1001\/jama.2010.1237"},{"key":"2026071213222502020_j_raon-2020-0020_ref_026_w2aab3b7b5b1b6b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"Patrono MG, Corzo C, Iniesta M, Ramirez PT. Management of pre-invasive lesions. Clin Obstet Gynecol 2017; 60: 771-9. doi: 10.1097\/ GRF.0000000000000316","DOI":"10.1097\/GRF.0000000000000316"},{"key":"2026071213222502020_j_raon-2020-0020_ref_027_w2aab3b7b5b1b6b1ab2ac27Aa","unstructured":"Genetic\/Familial High-Risk Assessment: Breast and Ovarian, version 3.2019, NCCN Guidelines, January 18, 2019. [cites 2019 Nov 15]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#detection"},{"key":"2026071213222502020_j_raon-2020-0020_ref_028_w2aab3b7b5b1b6b1ab2ac28Aa","doi-asserted-by":"crossref","unstructured":"Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, et al. Clinical and pathological characteristics of incidental diagnostic early occult malignancy after risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Int J Gynecol Cancer 2016; 26: 233-9. doi: 10.1097\/ IGC.0000000000000624","DOI":"10.1097\/IGC.0000000000000624"},{"key":"2026071213222502020_j_raon-2020-0020_ref_029_w2aab3b7b5b1b6b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 2014; 132: 280-6. doi: 10.1016\/j.ygyno.2013.12.009","DOI":"10.1016\/j.ygyno.2013.12.009"},{"key":"2026071213222502020_j_raon-2020-0020_ref_030_w2aab3b7b5b1b6b1ab2ac30Aa","doi-asserted-by":"crossref","unstructured":"Drescher CW, Anderson GL. The yet unrealized promise of ovarian cancer screening. JAMA Oncol 2018; 4: 456-7. doi: 10.1001\/jamaoncol.2018.0028","DOI":"10.1001\/jamaoncol.2018.0028"},{"key":"2026071213222502020_j_raon-2020-0020_ref_031_w2aab3b7b5b1b6b1ab2ac31Aa","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015; 313: 1347-61. doi: 10.1001\/ jama.2014.5985"},{"key":"2026071213222502020_j_raon-2020-0020_ref_032_w2aab3b7b5b1b6b1ab2ac32Aa","doi-asserted-by":"crossref","unstructured":"Stegel V, Krajc M, Zgajnar J, Teugels E, De Gr\u00e8ve J, Ho\u010devar M, et al. The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet 2011; 12: 9. doi: 10.1186\/1471-2350-12-9","DOI":"10.1186\/1471-2350-12-9"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/54\/2\/article-p180.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2020-0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:15:46Z","timestamp":1783905346000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2020-0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,28]]},"published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["10.2478\/raon-2020-0020"],"URL":"https:\/\/doi.org\/10.2478\/raon-2020-0020","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}